Schildkraut JM - Search Results

1

Perceived discrimination, trust in physicians, and prolonged symptom duration before ovarian cancer diagnosis in the African American Cancer Epidemiology Study.

Mullins MA, Peres LC, Alberg AJ, Bandera EV, Barnholtz-Sloan JS, Bondy ML, Funkhouser E, Moorman PG, Peters ES, Terry PD, Schwartz AG, Lawson AB, Schildkraut JM, Cote ML. Mullins MA, et al. Among authors: schildkraut jm. Cancer. 2019 Dec 15;125(24):4442-4451. doi: 10.1002/cncr.32451. Epub 2019 Aug 15. Cancer. 2019. PMID: 31415710 Free PMC article.

2

Ethical ramifications of alternative means of recruiting research participants from cancer registries.

Sugarman J, Regan K, Parker B, Bluman LG, Schildkraut J. Sugarman J, et al. Cancer. 1999 Aug 15;86(4):647-51. doi: 10.1002/(sici)1097-0142(19990815)86:4<647::aid-cncr13>3.0.co;2-g. Cancer. 1999. PMID: 10440692

3

Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.

Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Schildkraut JM, et al. J Natl Cancer Inst. 2002 Jan 2;94(1):32-8. doi: 10.1093/jnci/94.1.32. J Natl Cancer Inst. 2002. PMID: 11773280

4

Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States).

Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. Moorman PG, et al. Among authors: schildkraut jm. Cancer Causes Control. 2002 Nov;13(9):807-11. doi: 10.1023/a:1020678100977. Cancer Causes Control. 2002. PMID: 12462545

5

High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.

Lancaster JM, Sayer R, Blanchette C, Calingaert B, Whitaker R, Schildkraut J, Marks J, Berchuck A. Lancaster JM, et al. Among authors: schildkraut j. Clin Cancer Res. 2003 Feb;9(2):762-6. Clin Cancer Res. 2003. PMID: 12576447

6

No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.

Lancaster JM, Wenham RM, Halabi S, Calingaert B, Marks JR, Moorman PG, Bentley RC, Berchuck A, Schildkraut JM. Lancaster JM, et al. Among authors: schildkraut jm. Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):226-7. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12646513 No abstract available.

7

Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.

Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Vine MF, et al. Among authors: schildkraut jm. Gynecol Oncol. 2003 Jul;90(1):75-82. doi: 10.1016/s0090-8258(03)00175-6. Gynecol Oncol. 2003. PMID: 12821345

8

Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.

Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RC, Marks J, Berchuck A. Wenham RM, et al. Among authors: schildkraut jm. Clin Cancer Res. 2003 Oct 1;9(12):4396-403. Clin Cancer Res. 2003. PMID: 14555511

9

Racial differences in enrolment in a cancer genetics registry.

Moorman PG, Skinner CS, Evans JP, Newman B, Sorenson JR, Calingaert B, Susswein L, Crankshaw TS, Hoyo C, Schildkraut JM. Moorman PG, et al. Among authors: schildkraut jm. Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1349-54. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15298957

10

IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men.

Schildkraut JM, Demark-Wahnefried W, Wenham RM, Grubber J, Jeffreys AS, Grambow SC, Marks JR, Moorman PG, Hoyo C, Ali S, Walther PJ. Schildkraut JM, et al. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):403-8. doi: 10.1158/1055-9965.EPI-04-0426. Cancer Epidemiol Biomarkers Prev. 2005. PMID: 15734965

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

373 results

Search Page